-+ 0.00%
-+ 0.00%
-+ 0.00%
Gebel announced that the company's application for the marketing of the drug tergixetine hydrobromide, which is currently being developed, has recently been accepted by the State Drug Administration, and the marketing application for the relevant formulation is in progress. Follow-up work may still be affected by uncertainties, and the company will actively advance the follow-up process in accordance with relevant procedures.
Share
Listen to the news
Gebel announced that the company's application for the marketing of the drug tergixetine hydrobromide, which is currently being developed, has recently been accepted by the State Drug Administration, and the marketing application for the relevant formulation is in progress. Follow-up work may still be affected by uncertainties, and the company will actively advance the follow-up process in accordance with relevant procedures.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending